Test Price
2,800 AED✅ Home Collection Available
GM2A Gene Tay-Sachs Disease AB Variant Genetic Test in UAE
Executive Summary & Core Metrics
- ◆ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139). Full GM2A gene coverage with copy number variant (CNV) analysis included.
- ◆ Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy available 8 AM – 11 PM across all Emirates.
- ◆ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by DHA-licensed molecular diagnostics specialists.
- ◆ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. Pre-approval coordination for major UAE insurance networks.
Test Overview & Methodology
The GM2A Gene Tay-Sachs Disease AB Variant Genetic Test is a definitive molecular diagnostic assay that sequences the entire coding region of the GM2A gene using Next Generation Sequencing (NGS). This test is indicated for symptomatic patients, at-risk family members, and couples undergoing carrier screening in the UAE. Unlike traditional biochemical assays, NGS delivers comprehensive variant detection — including missense, nonsense, splice-site, and small insertion/deletion mutations — with superior analytical sensitivity. Results are interpreted in accordance with ACMG/AMP variant classification guidelines and cross-referenced against ClinVar and gnomAD population databases to ensure robust clinical reporting for the UAE's genetically diverse population.
Test Comparison: Our NGS Panel vs. Closest Alternative
| Feature | Our Test – GM2A NGS (DNA Labs UAE) | Closest Alternative – Single-Exon Sanger Sequencing |
|---|---|---|
| Detection Precision | 99.9% Sensitivity – Full gene with CNV analysis | ~85% Sensitivity – Misses deep intronic and CNV variants |
| Methodology | NGS (Next Generation Sequencing) – Illumina NovaSeq X Plus | Sanger Sequencing – Targeted exon-by-exon |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks (sequential processing) |
| Sample Flexibility | Blood, Extracted DNA, or Single Drop on FTA Card | Whole Blood (EDTA) only |
| UAE Regulatory Compliance | Federal Decree-Law No. 45 of 2021 (PDPL) | Federal Law No. 2 of 2019 | ISO 9001:2015 | Variable – May lack UAE-specific accreditation |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics | DHA Registration ID: 9294403) advises:
"A positive GM2A variant report must be interpreted within the full clinical context — it is not a standalone diagnostic endpoint. Correlation with biochemical enzyme assays measuring beta-hexosaminidase A and GM2 activator protein levels, combined with a detailed neurological evaluation and comprehensive family history, is essential before any clinical management decision is made."
"For couples identified as carriers during preconception screening, I recommend proceeding with a dedicated genetic counselling session to explore reproductive options — including prenatal diagnosis and preimplantation genetic testing (PGT) — in full compliance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability and Federal Law No. 2 of 2019 on health data protection."
"Our team is committed to delivering results with clinical empathy and interpretive precision. Genetic diagnoses carry profound emotional weight, and every patient and family deserves unhurried, compassionate communication throughout the testing journey."
Clinical Advisory: Medication and Therapeutic Stability
Do not discontinue, alter, or adjust any prescribed medication, supplement regimen, or therapeutic intervention based solely on genetic test results or in anticipation of testing. This genetic test is a diagnostic assessment tool and does not constitute treatment advice. Any modification to prescribed therapy must only occur under the direct supervision of your treating physician following a comprehensive clinical evaluation.
Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection:
- Patient is currently admitted to an intensive care unit (ICU) or high-dependency unit (HDU).
- Active febrile illness with temperature exceeding 38.5°C at time of scheduled collection.
- Known bleeding diathesis or therapeutic anticoagulation with INR > 3.0 (requires hospital-based phlebotomy).
- Patient is a minor (under 18 years) without documented parental or legal guardian consent.
- Inability to produce valid government-issued identification at the time of sample collection.
Emergency Red Flags — Seek Immediate Medical Attention:
- Rapid neurological deterioration: acute loss of motor milestones, sudden-onset seizures, or unexplained loss of consciousness.
- Progressive hypotonia (floppiness) in an infant combined with feeding difficulties and respiratory distress.
- Cherry-red macular spot identified on fundoscopic examination with concurrent developmental regression.
- Any acute psychiatric emergency, including suicidal ideation triggered by genetic counselling discussions.
If any of these red-flag symptoms are present, proceed directly to the nearest emergency department. Do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. What does the GM2A NGS test detect, and how is it different from standard Tay-Sachs testing?
This test comprehensively sequences the entire GM2A gene using Next Generation Sequencing to detect all pathogenic variants — including point mutations, small insertions/deletions, and copy number variants — responsible for Tay-Sachs disease AB variant (GM2 Activator Deficiency). This condition is clinically and biochemically distinct from classical Tay-Sachs disease (caused by HEXA gene mutations), therefore requiring this dedicated molecular assay for accurate diagnosis.
2. Why is genetic counselling mandatory before this test in the UAE?
Mandatory pre-test genetic counselling ensures that patients and families fully understand the autosomal recessive inheritance pattern of GM2A-associated disease, the implications of carrier status for future reproductive decisions, and the psychosocial impact of receiving a potentially life-altering genetic diagnosis. This requirement aligns with Federal Decree-Law No. 4 of 2016 on Medical Liability and the ethical standards upheld by the Dubai Health Authority.
3. How long do GM2A gene test results take in the UAE?
Full GM2A gene sequencing results via NGS are delivered within three to four weeks from sample receipt at our ISO 9001:2015 accredited laboratory in Dubai. This timeframe includes comprehensive variant bioinformatics analysis, clinical interpretation per ACMG/AMP guidelines, and multi-tiered quality review by our consultant medical genetics team.
4. Can a single drop of blood on an FTA card really yield reliable NGS results?
Yes. FTA card technology chemically stabilizes and preserves genomic DNA at ambient temperature. When processed through our validated NGS pipeline, a single dried blood spot yields DNA of sufficient quality and quantity to achieve 99.9% analytical sensitivity across the entire GM2A gene coding region with full reproducibility.
5. Does UAE health insurance cover the cost of the GM2A gene test?
Our laboratory provides direct insurance coverage verification via WhatsApp at +971 54 548 8731. We coordinate pre-approval with major UAE insurance networks to confirm coverage of the 2800 AED GM2A gene test according to each patient's policy. Coverage varies by insurer and plan; we recommend contacting our billing team for a personalized eligibility check.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Governance: All genetic data processed through this test is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These frameworks mandate encrypted data storage, patient consent protocols, and strict limitations on data sharing. Clinical safety and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Accreditation: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). DHA Facility License Number: 1143.
Contact & Support: WhatsApp +971 54 548 8731 | Phone +971545488731 | Home Collection: 8 AM – 11 PM Daily | DHA-Licensed Molecular Diagnostics Laboratory.
Clinical & Logistical Metadata
| Test Name | GM2A Gene Tay-Sachs Disease AB Variant Genetic Test (NGS) |
| Price (AED) | 2800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card (Dried Blood Spot) |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina NovaSeq X Plus with CNV Analysis |
| ICD-10-CM Code | E75.02 (Tay-Sachs Disease) | Z13.228 (Screening for Metabolic Disorders) | Z14.8 (Genetic Carrier Status) |
| LOINC Code | 101346-7 (GM2A Gene Full Sequence Analysis by NGS) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians